Dr. Peter Forsell

Stories

Implantica begins U.S. launch of RefluxStop after FDA approval

As of September 2026: Leading the U.S. commercial rollout

The Food and Drug Administration approved Implantica's RefluxStop device on August 20, clearing the way for the first new anti-reflux implant to enter the U.S. market since Johnson & Johnson's Linx. On September 29, the company kicked off its commercial launch at the American Foregut Society's annual meeting in Washington, drawing an over-capacity crowd of more than 120 surgeons and gastroenterologists. The launch venue was chosen to put the device in front of the specialists who decide which reflux patients get surgery.

Updated Sep 29

Notable Quotes

They have already decided to withdraw from all markets outside the U.S., and I would not be surprised if they also withdraw from the U.S. market in the near term as well.

from Implantica begins U.S. launch of RefluxStop after FDA approval · Updated Sep 29

With more than 40% of U.S. patients continuing to experience symptoms despite daily medication, we believe RefluxStop is perfectly positioned and timed to fill this massive treatment gap.

from Implantica begins U.S. launch of RefluxStop after FDA approval · Updated Sep 29